WO2004071389A3 - Non-steroidal infalmmation inhibitors - Google Patents
Non-steroidal infalmmation inhibitors Download PDFInfo
- Publication number
- WO2004071389A3 WO2004071389A3 PCT/EP2004/001507 EP2004001507W WO2004071389A3 WO 2004071389 A3 WO2004071389 A3 WO 2004071389A3 EP 2004001507 W EP2004001507 W EP 2004001507W WO 2004071389 A3 WO2004071389 A3 WO 2004071389A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- represents hydrogen
- nr8cor9
- conr8r9
- coor7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound of formula (I) wherein: n represents an integer 0, 1 or 2; X represents, O, S, NR6a, or CHR6b; R1 represents hydrogen, halogen such as F, Cl or Br, NO2, hydroxy, cyano, -OC1-6 alkoxy such as methoxy, C1-6 alkyl such as methyl, NR8R9 such as NH2, NR8COR9 such as -NHCHO or -NHCOCH3, COOR7 or CONR8R9; R2 represents hydrogen, halogen such as F, Cl, Br, NO2, hydroxy, cyano, -OC1-6 alkoxy such as methoxy, C1-6 alkyl such as methyl, NR8R9 such as NH2, NR8COR9 such as -NHCHO or -NHCOCH3, COOR7 or CONR8R9; R3 represents hydrogen, halogen such as F, Cl, Br, NO2, hydroxy, cyano, -OC1-6 alkoxy such as methoxy, C1-6 alkyl such as methyl, NR8R9 such as NH2, NR8COR9 such as -NHCHO or -NHCOCH3, COOR7, CONR8R9; R4 represents hydrogen, halogen such as F, Cl, Br, NO2, hydroxy, cyano, -OC1-6 alkoxy such as methoxy, C1-6 alkyl such as methyl, NR8R9 such as NH2, NR8COR9 such as -NHCHO or -NHCOCH3, COOR7 or CONR8R9; R5 represents H, C1-6 alkyl, or C1-6 alkenyl; R6a represents hydrogen, C1-6 alkyl, CO2C1-3 alkyl, COC1-3 alkyl or SO2C1-3 alkyl; R6b represents hydrogen, or C1-6 alkyl; R7 represents hydrogen, C1-6 alkyl, C1-3 alkyleneSiC1-3 alkyl such as -CH2CH2Si(CH3)3; R8 and R9 independently represent hydrogen or C1-6 alkyl; including pharmaceutically acceptable esters, amides and carbamates thereof, salts thereof, solvates thereof, and solvates of such pharmaceutically acceptable esters, amides, carbamates and salts.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0303523A GB0303523D0 (en) | 2003-02-15 | 2003-02-15 | Compounds |
| GB0303523.5 | 2003-02-15 | ||
| GB0305721.3 | 2003-03-13 | ||
| GB0305717A GB0305717D0 (en) | 2003-03-13 | 2003-03-13 | Compounds |
| GB0305717.1 | 2003-03-13 | ||
| GB0305721A GB0305721D0 (en) | 2003-03-13 | 2003-03-13 | Compounds |
| GB0316865.5 | 2003-07-18 | ||
| GB0316865A GB0316865D0 (en) | 2003-07-18 | 2003-07-18 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004071389A2 WO2004071389A2 (en) | 2004-08-26 |
| WO2004071389A3 true WO2004071389A3 (en) | 2004-12-02 |
Family
ID=32872852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/001507 Ceased WO2004071389A2 (en) | 2003-02-15 | 2004-02-13 | Non-steroidal infalmmation inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2004071389A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60318188T2 (en) | 2002-03-26 | 2008-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | GLUCOCORTICOID MIMETICS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USE |
| UY28526A1 (en) | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME |
| US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
| WO2006000398A1 (en) * | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| EP1836166B1 (en) * | 2004-12-27 | 2009-06-17 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| GB0513297D0 (en) * | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| GB0611587D0 (en) * | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| WO2008000777A2 (en) * | 2006-06-29 | 2008-01-03 | Glaxo Group Limited | Phenyl- pyrazole derivatives, process for their preparation and their pharmaceutical use |
| KR20090097908A (en) | 2006-12-06 | 2009-09-16 | 베링거 인겔하임 인터내셔날 게엠베하 | Glucocorticoid mimetics, methods of preparation thereof, pharmaceutical compositions and uses thereof |
| JP2010513394A (en) * | 2006-12-20 | 2010-04-30 | グラクソ グループ リミテッド | Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands |
| EP2300472B1 (en) | 2008-06-06 | 2012-01-18 | Boehringer Ingelheim International GmbH | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US9382245B2 (en) | 2013-10-11 | 2016-07-05 | Yale University | Compounds and methods for treating HIV infections |
| CA3209170A1 (en) * | 2021-03-23 | 2022-09-29 | Eli Lilly And Company | Glucocorticoid receptor agonists |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000032584A2 (en) * | 1998-11-27 | 2000-06-08 | Schering Aktiengesellschaft | Nonsteroidal antiinflammatories |
| WO2002010143A1 (en) * | 2000-07-28 | 2002-02-07 | Schering Aktiengesellschaft | Non-steroidal inflammation inhibitors |
-
2004
- 2004-02-13 WO PCT/EP2004/001507 patent/WO2004071389A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000032584A2 (en) * | 1998-11-27 | 2000-06-08 | Schering Aktiengesellschaft | Nonsteroidal antiinflammatories |
| WO2002010143A1 (en) * | 2000-07-28 | 2002-02-07 | Schering Aktiengesellschaft | Non-steroidal inflammation inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004071389A2 (en) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004071389A3 (en) | Non-steroidal infalmmation inhibitors | |
| TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| EP1760073A4 (en) | Sulfonamide compound | |
| WO2004013101A3 (en) | N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | |
| NO20062031L (en) | Derivatives of N- [phenyl (alkylpeptidn-2-yl) methyl] benzamide, process for its preparation and use in therapeutic media | |
| ES2543607T3 (en) | Certain substituted amides, method of obtaining, and method of use | |
| WO2007081571A3 (en) | Cetp inhibitors | |
| WO2005074643A3 (en) | Benzamide compounds useful as rock inhibitors | |
| HRP20090195T1 (en) | MITOTIC CHINESE INHIBITORS | |
| EA200501730A1 (en) | DERIVATIVES N-PYRROLIDIN-3-IL-AMIDA AS AN INHIBITORS OF REVERSE CAPTURE OF SEROTONIN AND NORADRENALINE | |
| DK1485377T5 (en) | Pyranones are suitable as ATM inhibitors | |
| PE20011115A1 (en) | TRI-ARIL-SUBSTITUTED ETHANS, PDE4 INHIBITORS | |
| HUP0302930A2 (en) | Process for the preparation n-(substituted phenyl)-3-alkyl-,aryl- and heteroaryl-sulfonil-2-hydroxy-2-alkyl- and haloalkylpropanamide compounds | |
| EA200600607A1 (en) | IMIDAZOPIRIDIN DERIVATIVES AS AN INDUCED NO SYNTHASE INHIBITORS | |
| HRP20030610B1 (en) | Process for the preparation of mesylates of piperazine derivatives | |
| ATE374750T1 (en) | SEROTONIN RUPUP INHIBITORS | |
| TNSN08161A1 (en) | 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof | |
| TW200637539A (en) | CTGF inhibitors | |
| EP1798227A4 (en) | Serotonin 5-ht3 receptor agonist | |
| NO20061832L (en) | Carbamide derivatives of amide type | |
| GB0326964D0 (en) | Chemical compounds | |
| WO2001044228A3 (en) | Derivatives of quinazolinedione phthalimide, preparations thereof and their therapeutic uses | |
| EA200600608A1 (en) | IMIDAZOPIRIDINE DERIVATIVES AS INDUCED NO-SYNTHASE INHIBITORS | |
| WO2006026034A3 (en) | Processes for the preparation of isothiazole derivatives | |
| PL1637141T3 (en) | Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |